The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary fibrosis
The fibrosis caused by nitrosoureas has the reputation for being severe, progressive and fatal
Publications
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
BMC cancer 2010 Feb 02;10;30 — 2010 Feb 02 — 30
Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity.
Chest 2004 Dec;126;2007-13 — 2004 Dec — 2007-13
Pulmonary fibrosis following low-dose 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) therapy.
Cancer 1980 Mar 15;45;1311-4 — 1980 Mar 15 — 1311-4
Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.
Cancer 1983 May 15;51;1814-8 — 1983 May 15 — 1814-8
Pulmonary toxicity of lomustine.
Cancer treatment reports 1987 Jul-Aug;71;786-7 — 1987 Jul-Aug — 786-7
Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea.
Chest 1977 Sep;72;372-3 — 1977 Sep — 372-3
Fatal pulmonary fibrosis following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.
Cancer 1978 Jul;42;74-6 — 1978 Jul — 74-6
Nitrosourea-associated pulmonary fibrosis.
Cancer treatment reports 1979 Nov-Dec;63;2128-30 — 1979 Nov-Dec — 2128-30